GlassScriptPhysician profile
Sujata Chava
NPI 1043318090
$1,804.61
in general payments reported to CMS, 2019-2025
18 companies · $96.30 in 2025
The $96.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $161 · 2021: $352 · 2022: $240 · 2023: $488 · 2024: $348 · 2025: $96.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $295.82 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $277.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $237.09 | 2020-2025 | |
| Novo Nordisk INC | $224.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $124.49 | 2022 | |
| Abbvie INC. | $86.69 | 2021-2023 | Viberzi, Linzess |
| Exact Sciences Corporation | $77.01 | 2023-2024 | Cologuard Collection Kit |
| Phadia US INC. | $75.50 | 2019-2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.12 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.24 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $45.17 | 2022-2023 | Freestyle Libre |
| Sanofi Pasteur INC. | $45.04 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $41.54 | 2021-2024 | Gardasil, Vaxelis, Capvaxive |
| Organon LLC | $38.07 | 2025 | Nexplanon |
| Viiv Healthcare Company | $34.20 | 2024 | Apretude |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.61 | 2021-2023 | |
| Glaxosmithkline, LLC. | $18.85 | 2024 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $17.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujata Chava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.